Earnings NYSE Nasdaq 100 U.S. Tech Politics AI Science SEC Business Wall Street Energy Bitcoin (BTC) Dow Jones Dividend NVIDIA (NVDA) Investing Markets Economy S&P 500 China World Donald Trump Fed Crude Oil Money Inflation Tesla (TSLA) Gold Software U.K. Entertainment Apple (AAPL) Health Amazon (AMZN) Retail Wealth Taxes Elon Musk Europe Real Estate Retirement Natural Gas 3M (MMM) Microsoft (MSFT) Security Meta Platforms (META) Current Canada Options Truist Financial Corp (TFC) Boeing (BA) Hedge Funds Jim Cramer Tax Insurance Google Sports Live Manufacturing Cars Pharmaceuticals Economics Warren Buffett War Ukraine Airlines Costco (COST) Mining Holidays Finance Japan York Silver Construction Interest Rates Goldman Sachs (GS) New York BlackRock (BLK) Walmart (WMT) Kamala Harris OpenAI ChatGPT Space Mortgage REITs Internet JPMorgan (JPM) Aerospace Ethereum (ETH) Enterprise Intel (INTC) Walt Disney (DIS) GBP USD Netflix (NFLX) India Texas IPOs Morgan Stanley (MS) AustraliaMore +
Stock Market News Stock Market News
  • Stocks
  • ETFs
  • Bonds
  • Commodities
  • Earnings
  • Dividends
  • REITs
  • IPOs
  • Cryptocurrency
  • Forex
  • Tech
  • Politics
  • +

3 days Biomarin: Challanges Mount, But Sale Rumours Make For A Risky “Buy” CallSeeking Alpha

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky “Buy” Call.

Biomarin Pharma (BMRN)

X       

2 days Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024?Insider Monkey X       

3 days Here’s Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockZacks X       

4 days Here’s Why BioMarin Pharmaceutical (BMRN) is a Strong Growth StockZacks X       

2 weeks Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)Insider Monkey X       

3 weeks Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think “Yes”Zacks X       

3 weeks BioMarin (BMRN) Upgraded to Buy: Here’s WhyZacks X       

3 weeks BMRN vs. INCY: Which Stock Is the Better Value Option?Zacks X       

3 weeks Earnings call: BioMarin reports robust Q3 growth with VOXZOGO sales surgeInvesting.com X       

4 weeks Royal Bank of Canada Reiterates “Sector Perform” Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)MarketBeat X       

4 weeks BioMarin Q3 Earnings & Revenues Beat Estimates, ’24 Guidance RaisedZacks X       

4 weeks BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call TranscriptSeeking Alpha X       

4 weeks BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks X       

1 month BioMarin Pharmaceutical (BMRN) to Release Quarterly Earnings on TuesdayMarketBeat X       

More news +
Home | Contact
  • X

© 2024 The Stock Market News